During the last session, Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s traded shares were 1.2 million, with the beta value of the company hitting 0.60. At the end of the trading day, the stock’s price was $1.10, reflecting an intraday loss of -5.17% or -$0.06. The 52-week high for the CMMB share is $2.55, that puts it down -131.82 from that peak though still a striking 47.27% gain since the share price plummeted to a 52-week low of $0.58. The company’s market capitalization is $20.75M, and the average intraday trading volume over the past 10 days was 0.21 million shares, and the average trade volume was 353.31K shares over the past three months.
Chemomab Therapeutics Ltd ADR (CMMB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CMMB has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.01.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) trade information
Chemomab Therapeutics Ltd ADR (CMMB) registered a -5.17% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.17% in intraday trading to $1.10, hitting a weekly high. The stock’s 5-day price performance is -18.52%, and it has moved by -32.52% in 30 days. Based on these gigs, the overall price performance for the year is 51.31%. The short interest in Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) is 0.27 million shares and it means that shorts have 0.31 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 44.09%. While earnings are projected to return -806.98% in 2025.
CMMB Dividends
Chemomab Therapeutics Ltd ADR is due to release its next quarterly earnings on 2025-Mar-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s Major holders
Chemomab Therapeutics Ltd ADR insiders own 15.90% of total outstanding shares while institutional holders control 25.92%, with the float percentage being 30.83%.
